100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications.

IF 7.6 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2024-10-01 DOI:10.1016/j.ejca.2024.114624

A. Tedeschi, D.H. Peng, F. Schischlik-Siegl, O. Schaaf, D. Gerlach, F. Rocchetti, J. Popow, J. Broeker, T. Wunberg, A.S. Boghossian, M.G. Rees, M.M. Ronan, J.A. Roth, M. Williams, C. Vellano, J.R. Marszalek, T.P. Heffernan, M. Pearson, N. Kraut, R. Dorothea

引用次数: 0

查看原文本刊更多论文

100（PB088）：KRAS 多种抑制剂 BI 3706674 在 KRAS 驱动的癌症临床前模型中显示出疗效，支持对携带 KRASG12V 突变和 KRAS 野生型扩增的肿瘤患者进行临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.